Figure 1. Comparisons of cabotegravir post-hoc estimates of pharmacokinetic parameters (a – c) and plasma exposures (d – i) in Asian and non-Asian participants. Pharmacokinetic parameters included (a) KALA, (b) weight-normalized CL/F, and (c) weight-normalized V2/F. Exposures included Cmax (a, b, c) and Ctau (d, e, f) following the initiation injection (a, d), at steady state of QM injections (b, e), and at steady state of Q2M injections (c, f). Boxes represent interquartile ranges; solid horizontal lines represent medians; error bars represent 5th and 95th percentiles; solid circles represent individual values (individual values for non-Asian participants are not displayed for cosmetic reason). Horizontal dashed lines represent minimum and maximum values in non-Asian participants. CL/F = apparent central clearance; Cmax = maximum concentration; Ctau = trough concentration; KALA = long-acting absorption rate constant; Q2M = once every 2 months; QM = once monthly; V2/F = apparent central volume of distribution; WT = body weight.
